Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 3 2Phase NA 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 4Esophageal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Radiation Pneumonitis 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1Non-squamous Non-small-cell Lung Cancer 1Neoplasms by Site 1Lung Diseases 1Locally Advanced Gastric Cancer 1Esophageal Malignant Neoplasm, Local Recurrence 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1Breast Neoplasms 1Advanced NSCLC 1Advanced Esophageal Cancer 1

Interventions

Oxaliplatin 56Capecitabine 49Fluorouracil 37Cisplatin 37S 1 (combination) 23Paclitaxel 18Docetaxel 18Leucovorin 16pembrolizumab 13Irinotecan 12apatinib 11titanium silicide 9XELOX 9Trastuzumab 9Nivolumab 9Hyperthermic Intraperitoneal Chemotherapy 8Epirubicin 8Drug Therapy 8Tegafur 7Radiotherapy 6Neoadjuvant Therapy 6gimeracil 5Surgical Procedures, Operative 5Gastrectomy 5Chemotherapy, Adjuvant 5tislelizumab 4S-1 plus cisplatin 4Ramucirumab 4zolbetuximab 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Stomach Neoplasms × camrelizumab × Clear all
NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
550 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
885 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡